Regulatory
Kala Pharmaceuticals’ Eysuvis (loteprednol etabonate ophthalmic suspension) Receives US FDA’s
Shots: The approval is based on results from four clinical trials, including three P-III trials and one P-II trial, that demonstrated significant improvements in both the signs and symptoms of dry eye disease The approval has made Eysuvis, the 1st ocular corticosteroid for the treatment of dry eye disease and the 1st drug approved specifically […]Read More
